US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
アメリカ
USOTC
Bank of Nagoya Ltd (PK) (BNGYF) 銘柄情報

Bank of Nagoya Ltd (PK) (BNGYF)

12.0488

0.00

(0.00%)

終了 7月5日 5:00AM

Bank of Nagoya Ltd (PK) (BNGYF) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

12.0488

( - )

買値

0.00

売値

0.00

出来高

-

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

12.0488

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 158,670

発行済株式数

49,196,997

配当利回り

170

PER

14.8

1 株当たり利益 (EPS)

412.05

歳入

102.52B

純利益

20.27B

The Bank of Nagoya, Ltd. provides various banking, financial leasing, and credit card services in Japan. The company operates through Banking, Leasing, and Credit Card segments. It offers deposits and loans; domestic and foreign exchange transactions; securities investments; trading securities trans... The Bank of Nagoya, Ltd. provides various banking, financial leasing, and credit card services in Japan. The company operates through Banking, Leasing, and Credit Card segments. It offers deposits and loans; domestic and foreign exchange transactions; securities investments; trading securities transactions; and underwriting and registration of corporate bonds. The company also engages in clerical outsourcing businesses. The Bank of Nagoya, Ltd. was incorporated in 1949 and is based in Nagoya, Japan. 詳細を表示

セクター

Finance

業界

Banking

ウェブサイト

www.meigin.com

本社

Nagoya, Japan

設立

2026

Bank of Nagoya Ltd (PK) is listed in the Finance sector of the その他OTC with ticker BNGYF. The last closing price for Bank of Nagoya (PK) was US$12.05. Over the last year, Bank of Nagoya (PK) shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Bank of Nagoya (PK) currently has 49,196,997 shares in issue. The market capitalisation of Bank of Nagoya (PK) is US$592.76 million. Bank of Nagoya (PK) has a price to earnings ratio (PE ratio) of 14.80.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

BNGYF - Frequently Asked Questions (FAQ)

What is the current Bank of Nagoya Ltd (PK) share price?

The current share price of Bank of Nagoya Ltd (PK) is US$ 12.0488

How many Bank of Nagoya Ltd (PK) shares are in issue?

Bank of Nagoya Ltd (PK) has 49,196,997 shares in issue

What is the market cap of Bank of Nagoya Ltd (PK)?

The market capitalisation of Bank of Nagoya Ltd (PK) is USD 592.76M

What is the 1 year trading range for Bank of Nagoya Ltd (PK) share price?

Bank of Nagoya Ltd (PK) has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Bank of Nagoya Ltd (PK)?

The price to earnings ratio of Bank of Nagoya Ltd (PK) is 14.8

What is the cash to sales ratio of Bank of Nagoya Ltd (PK)?

The cash to sales ratio of Bank of Nagoya Ltd (PK) is 2.93

What is the registered address of Bank of Nagoya Ltd (PK)?

The registered address for Bank of Nagoya Ltd (PK) is 19-17 Nishiki 3-chome, Nagoya, Aichi, 460-0003

What is the Bank of Nagoya Ltd (PK) website address?

The website address for Bank of Nagoya Ltd (PK) is www.meigin.com

Which industry sector does Bank of Nagoya Ltd (PK) operate in?

Bank of Nagoya Ltd (PK) operates in the Banking sector

weenphan

weenphan 9分前

https://www.otcmarkets.com/stock/CVALF/profile

Kool Aid Man

Kool Aid Man 10分前

Measly $44k left in the gas tank

40 million shares left to issue x .0011

No one goes public if they intend to self finance operations. The whole point is to print and sell shares to raise money...not to reward old bag holders who were conned by Miro years ago. Why split

jondoeuk

jondoeuk 11分前

Calling this the "gold standard" doesn't answer all the underlying concerns. This isn't a refinement of the original external-control analysis either. It uses a completely different set of external comparator trials. That means the reported survival estimate depends on which external patients are se

manibiotech

manibiotech 13分前

Yes we all know that . The previous external control arm patients were “external” , and the one’s in new PSM analysis are also different ‘external’ patients with patient level propensity matching ( so even better controls) and show even better treatment benefit . So again, what is the point you are

Naught

Naught 13分前

Should we expect some notices from. PAC in the very near term then...?

weenphan

weenphan 14分前

I posted on the PCHM board for over a decade. I bought PCHM as low as .0013 and sold stock as high as $5 plus. It was a once in a lifetime percentage gainer. My aliases were LMLYP, Rosesarefree and GeneandDean, which all are references to a band Ween. I'm weenphan on this board.

newflow

newflow 14分前

Ron, Dissolved vs Extinct
No Altaba distributed immediately before dissolution, can you find any company distributing value to equity holders after its complete dissolution long-form or regular Dissolution.
Gemini's Response:
It is important to clarify a key point about Delaware

DA88

Can someone explain who this guy is and why his perspective matters? Love that he is positive, but he doesn’t look like he is anything more than a shareholder.

PickStocks

PickStocks 17分前

Yes….but we do not have anything to do with Paladin. So it means nothing which is easily verified by a simple phone call….

jondoeuk

jondoeuk 21分前

Whether this particular analysis has been submitted is something nobody outside NWBO and the MHRA knows.

jondoeuk

jondoeuk 23分前

This is not simply a refinement of the published JAMA Oncology analysis. It's a different external-control analysis built from a different pool of comparator trials. The fact they constructed a propensity-score matched analysis using individual patient data from AVAGLIO, CENTRIC, and CORE, means the

ihorchu

ihorchu 25分前

A fantastic day to remember! Since no humidity here, heat is very tolerable.

jondoeuk

jondoeuk 31分前

'While encouraging, our clinical findings must be interpreted with caution. Even though this was a randomized clinical trial (randomization software assigned patients to TLR agonist/placebo groups), the small number of patients enrolled contributed to an imbalance in patient selection between the tr

kevindenver

kevindenver 31分前

Nowhere in the interview was "Blarcamesine" mentioned. There was a snippet towards the end where autophagy is mentioned.

Maybe you hallucinated that this interview was related to blarcamesine?

A transcript of the interview can be found here:
https://podcasts.hap

TightCoil

TightCoil 39分前

Yes, next week is the week we FLY

TightCoil

TightCoil 41分前

FNMA/FMCC
On Schwab Now
FNMA ask $7.33
FMCC ask $9.31
Load up Early
Remember:Again- Will you be quick enough to grab some of these shares once one or more current "announcements in the making," are made? Will you be quicker than the big gun buying stampede when eve

JonDoe1

JonDoe1 42分前

He's extra angry today. Possibly hit the 4th of July drinks a little early. That poor keyboard.

kenjiroo

kenjiroo 42分前

Happy 4th longs !!!

US Market News

US Market News 43分前

SK Telecom Pursues 15GW AI Data Center Buildout, Aiming to Become Asia's AI Infrastructure HubJuly 4, 2026 8:29 PM
PR Newswire (US) Ulsan AI Data Center to expand to GW scale; 5GW to be activated in stages from 2029, reaching 15GW in to

long_haul

long_haul 43分前

I like this guy a lot ! Next week is going to be fire

JonDoe1

JonDoe1 43分前

STOP RESPONDING TO MY POSTS

It's a public forum.

garyhalvo

garyhalvo 46分前

IMO, September 13th will probably end because I believe that all of those dates that were posted with the court has come and went, so I don’t see anything in the way. How long will it be till we get our money after that, I think by the end of September.

CHILLWILL1704

CHILLWILL1704 46分前

wheres the restaurant--I wanna go say hi-any body else want to go?

imafan

imafan 49分前

Shorts and Eric haters, you'll know who they are when they respond, have got to be extremely disappointed Eric is succeeding! They'll be more HUUUUGE confirmed announcements coming SHORTly! Sooo Entertaining!!! ONWARD!!!

Bank of Nagoya (PK)

AT & S Austria Technolog...

Abercrombie & Fitch

CAD vs Sterling

Inmolecule Nanotech

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。